Profil wykonawcy
VIIVHIV HEALTHCARE, UNIPESSOAL, LDA
PT- Zamówienia
- 16
- Łączna wartość zamówień
- 19 735 269 €
- Kraje
- countries.PT
- Ostatnie zamówienie
- 7 lip 2026
- Wygasają w ciągu 12 miesięcy
- 0
Historia zamówień
| Data | Zamawiający | Tytuł | Kategoria | Wartość | Kraj | Wygasa | Źródło |
|---|---|---|---|---|---|---|---|
| 07.07.2026 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Pharmaceutical products – 2024/0900 - DOLUTEGRAVIR + ABACAVIR + LAMIVUDINA [50 MG + 600 MG + 300 MG CÁP/COMP] | Produkty farmaceutyczne | 1,9 mln € | PT | — | Zobacz w TED ↗ |
| 07.07.2026 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Pharmaceutical products – 2024/0900 - DOLUTEGRAVIR + ABACAVIR + LAMIVUDINA [50 MG + 600 MG + 300 MG CÁP/COMP] | Produkty farmaceutyczne | 373,0 tys. € | PT | — | Zobacz w TED ↗ |
| 30.06.2026 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Pharmaceutical products – 2024/0900 - DOLUTEGRAVIR + RILPIVIRINA [50 MG + 25 MG CÁP/ COMP] | Produkty farmaceutyczne | 232,6 tys. € | PT | — | Zobacz w TED ↗ |
| 30.06.2026 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Pharmaceutical products – 2024/0900 - DOLUTEGRAVIR + RILPIVIRINA [50 MG + 25 MG CÁP/ COMP] | Produkty farmaceutyczne | 166,9 tys. € | PT | — | Zobacz w TED ↗ |
| 30.06.2026 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Pharmaceutical products – 2024/0900 - DOLUTEGRAVIR [50 MG CÁP/COMP] | Produkty farmaceutyczne | 434,3 tys. € | PT | — | Zobacz w TED ↗ |
| 12.05.2026 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2024/0900 - LAMIVUDINA + DOLUTEGRAVIR [300 MG + 50 MG COMP] | — | 942,7 tys. € | PT | — | Zobacz w TED ↗ |
| 16.12.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2024/0900 - LAMIVUDINA + DOLUTEGRAVIR [300 MG + 50 MG COMP] | — | 3,7 mln € | PT | — | Zobacz w TED ↗ |
| 17.06.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2024/0900-DOLUTEGRAVIR + RILPIVIRINA [50 MG + 25 MG; CÁP/ COMP] (D564) | — | 759,7 tys. € | PT | — | Zobacz w TED ↗ |
| 17.06.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2024/0900-DOLUTEGRAVIR + RILPIVIRINA [50 MG + 25 MG; CÁP/ COMP] (D564) | — | 152,3 tys. € | PT | — | Zobacz w TED ↗ |
| 23.04.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2024/0900 - DOLUTEGRAVIR [50 MG; CÁP/COMP] (D502) | — | 2,5 mln € | PT | — | Zobacz w TED ↗ |
| 23.04.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2024/0900 - Medicamentos antirretrovíricos para o tratamento da infeção por VIH (D503) | — | 2,6 mln € | PT | — | Zobacz w TED ↗ |
| 23.04.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2024/0900 - Medicamentos antirretrovíricos para o tratamento da infeção por VIH (D503) | — | 528,0 tys. € | PT | — | Zobacz w TED ↗ |
| 23.04.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2024/0900 - DOLUTEGRAVIR [50 MG; CÁP/COMP] (D502) | — | 499,0 tys. € | PT | — | Zobacz w TED ↗ |
| 15.04.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2024/0900-Medicamentos antirretrovíricos para o tratamento da infeção por VIH (L1061) | — | 3,8 mln € | PT | — | Zobacz w TED ↗ |
| 15.04.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – General anti-infectives for systemic use, vaccines, antineoplastic and immunodulating agents – 2024/0900-Medicamentos antirretrovíricos para o tratamento da infeção por VIH (L1061) | — | 400,4 tys. € | PT | — | Zobacz w TED ↗ |
| 15.04.2025 | Unidade Local de Saúde Santa Maria, E.P.E. | Portugal – Antineoplastic and immunomodulating agents – 2024/0900-Medicamentos antirretrovíricos para o tratamento da infeção por VIH (L1061) | — | 765,2 tys. € | PT | — | Zobacz w TED ↗ |